Workflow
北大医药股份有限公司关于公司全资子公司与北京大学国际医院关联交易事项的进展公告

Group 1 - The company has a long-term service contract with Peking University International Hospital for the supply and distribution of medical equipment, surgical instruments, drugs (excluding special drugs), in vitro diagnostic reagents, and medical consumables, which is set to expire in May 2025 [2][4] - The company’s subsidiary, Beijing Beiyi Pharmaceutical Co., Ltd., is currently the sole provider for these services, and its main revenue source is from the International Hospital [3][4] - Following the expiration of the contract, the International Hospital will switch to a bidding process for the supply of in vitro diagnostic reagents and medical consumables, which poses a risk to the company if it fails to win the bid [3][4] Group 2 - The termination of the business cooperation with the International Hospital is expected to result in a revenue decrease of approximately 600 million yuan and a net profit decrease of about 40 million yuan starting from June 2025 [4] - The company plans to actively collect receivables from the International Hospital and focus on enhancing its core pharmaceutical manufacturing business to mitigate the impact of the expected revenue and profit decline [4]